- Lee and AstraZeneca: India's next David and Goliath compulsory license fight?
- India rejects Bayer Nexavar CL appeal
- India Sprycel CL saga: BDR 'communicating' with BMS
- India Shuns Onglyza Compulsory License But Lee To Fight On?
- Interview: Cipla's heiress on taking the legacy forward & the firm's new baby
- Innovation not M&A to drive Bayer growth in LatAm